Clinical Trial Update: Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reports on the efficacy of nafamostat mesylate for COVID-19 pneumonia in Phase 2 and Phase 3; no current status available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corona Virus Infection

Drugs mentioned

• Nafamostat Mesylate (nafamostat)

Snippet

Sponsor: Gyeongsang National University Hospital | Conditions: Corona Virus Infection, COVID-19 | Phase 2, Phase 3 | Status: UNKNOWN